Last reviewed · How we verify
Zinc-l-carnosine
Zinc-l-carnosine forms a chelate complex that protects and promotes healing of the gastrointestinal mucosa by reducing oxidative stress and enhancing mucosal defense mechanisms.
Zinc-l-carnosine forms a chelate complex that protects and promotes healing of the gastrointestinal mucosa by reducing oxidative stress and enhancing mucosal defense mechanisms. Used for Gastric ulcer, Gastritis, Gastrointestinal mucosal damage and inflammation.
At a glance
| Generic name | Zinc-l-carnosine |
|---|---|
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Drug class | Mucosal protectant / Gastroprotective agent |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Zinc-l-carnosine is a dipeptide chelate compound that combines zinc with l-carnosine to provide cytoprotective effects in the gastrointestinal tract. It works by scavenging reactive oxygen species, stabilizing mast cells, and promoting mucosal regeneration and barrier function. The compound has been shown to reduce inflammation and support healing of damaged gastric and intestinal tissue.
Approved indications
- Gastric ulcer
- Gastritis
- Gastrointestinal mucosal damage and inflammation
Common side effects
- Generally well-tolerated with minimal adverse events
Key clinical trials
- A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes (NA)
- Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux (NA)
- Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers (PHASE1)
- Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC (PHASE1, PHASE2)
- Clinical Trials of Five Different Food Supplements With Restriction Diet in Adults (NA)
- Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV (NA)
- Efficacy of Zinc L-Carnosine Mouth Rinse (PHASE3)
- Zinc-L-Carnosine Prevents Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zinc-l-carnosine CI brief — competitive landscape report
- Zinc-l-carnosine updates RSS · CI watch RSS
- Fondazione IRCCS Policlinico San Matteo di Pavia portfolio CI